trial · primary record
Tobemstomig
Renal Cell Carcinoma
| Phase | Phase 2 |
|---|---|
| Status | COMPLETED |
| Sponsor | Unknown |
| Enrolment | 199 |
| Primary completion | 2026-10-05 |
| Primary endpoint | Incidence and Severity of Adverse Events (AEs) |
| Registry ID | NCT05805501 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:51.392Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05805501
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.